Nuvalent Inc (NUVL) - Total Liabilities
Based on the latest financial reports, Nuvalent Inc (NUVL) has total liabilities worth $156.78 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nuvalent Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Nuvalent Inc's total liabilities have evolved over time, based on quarterly financial data. See NUVL working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Nuvalent Inc Competitors by Total Liabilities
The table below lists competitors of Nuvalent Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Petronas Chemicals Group Bhd
KLSE:5183
|
Malaysia | RM20.58 Billion |
|
Akbank TAS
IS:AKBNK
|
Turkey | TL3.34 Trillion |
|
Huadian Energy
SHG:600726
|
China | CN¥26.10 Billion |
|
Hella KGaA Hueck & Co
XETRA:HLE
|
Germany | €4.17 Billion |
|
Yangzhou Yangjie Electronic Technology Co Ltd
SHE:300373
|
China | CN¥6.67 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €294.60 Million |
|
Brenntag SE
F:BNR
|
Germany | €6.28 Billion |
|
Enlight Renewable Energy Ltd
TA:ENLT
|
Israel | ILA6.88 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Nuvalent Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NUVL market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuvalent Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuvalent Inc (2019–2025)
The table below shows the annual total liabilities of Nuvalent Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $164.37 Million | +128.41% |
| 2024-12-31 | $71.96 Million | +126.13% |
| 2023-12-31 | $31.82 Million | +63.35% |
| 2022-12-31 | $19.48 Million | +121.70% |
| 2021-12-31 | $8.79 Million | -79.06% |
| 2020-12-31 | $41.97 Million | +104.01% |
| 2019-12-31 | $20.57 Million | -- |
About Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine k… Read more